A research team headed by Prof. Mats Ohlin of the Dept. of Immunotechnology has received funding for studies and development of human antibodies specific for the SARS-CoV-2 virus, the virus that cause COVID-19. The collaborative team includes researchers at Lund University, Skåne University Hospital, the Karolinska Institute, and the Royal Institute of Technology.